Efficacy and Safety of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

Medicine, Hematology, Oncology, Life Sciences, Immunology,
Multiple Myeloma   Teclistamab   BCMA-targeted therapy   Relapsed/Refractory   Clinical Trial  

Interpretation of Research on the Efficacy and Safety of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma Following Anti-BCMA Therapies Academic Background Multiple myeloma (MM) is a malignancy stemming from plasma cells within the bone marrow. Recent advancements in treatment have significantly improved overall survival rates. How...

Focal Deletions of a Promoter Tether Activate the IRX3 Oncogene in T-Cell Acute Lymphoblastic Leukemia

Medicine, Hematology, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology, Genetics,
T-cell acute lymphoblastic leukemia   FTO gene   IRX3 oncogene   enhancer hijacking   CTCF binding site   noncoding genome   tumor suppressor mechanism  

Stage-specific Chromosomal Deletions Activate the IRX3 Oncogene in T-cell Acute Lymphoblastic Leukemia In the field of cancer research, understanding regulatory mechanisms of the noncoding genome remains a key focus, especially concerning how oncogenes can be aberrantly activated through non-canonical regulatory pathways. This paper, authored by Su...

Bleeding Events in Patients with Cancer: Incidence, Risk Factors, and Impact on Prognosis in a Prospective Cohort Study

Medicine, Hematology, Oncology,
cancer   bleeding events   risk factors   prognosis   prospective study   anticoagulation   mortality  

The Incidence, Risk Factors, and Prognostic Impact of Bleeding Risk in Cancer Patients: A Review of the Vienna Cancer, Thrombosis, and Bleeding Study Academic Background and Research Motivation Cancer patients frequently experience hemostatic dysregulation, yet existing research has primarily focused on cancer-associated venous thromboembolism (VTE...

Selective Targeting of Mutated Calreticulin by the Monoclonal Antibody INCA033989 Inhibits Oncogenic Function of MPN

Medicine, Hematology, Oncology, Life Sciences, Immunology,
mutated calreticulin   monoclonal antibody   myeloproliferative neoplasms   targeted therapy   oncogenic function   INCA033989   hematopoiesis  

Report on the Academic Paper on the Monoclonal Antibody INCA033989 for Targeting Mutated Calreticulin in Myeloid Tumors Background: Calreticulin Mutation-Driven Myeloproliferative Neoplasms Myeloproliferative neoplasms (MPNs) are hematological malignancies caused by somatic mutations occurring in multipotent hematopoietic stem cells (HSCs). These m...

Antimetabolite Dose Intensity and Adverse Outcomes in Children with Acute Lymphoblastic Leukemia: A COG-AALL03N1 Report

Medicine, Pediatrics, Hematology, Oncology,
Acute Lymphoblastic Leukemia   Antimetabolite   Dose Intensity   Children   Toxicity   Relapse Risk   Treatment Adherence  

Review of the Study on Antimetabolite Dose Intensity and Adverse Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) Background and Research Question Acute Lymphoblastic Leukemia (ALL) is the most common form of leukemia in children. Current treatment strategies include risk-based induction therapy, response-adapted post-induction therapy,...

Diagnostic Guidelines for Familial Hemophagocytic Lymphohistiocytosis Revisited

Medicine, Pediatrics, Hematology, Life Sciences, Immunology, Genetics,
Familial Hemophagocytic Lymphohistiocytosis   Diagnostic Criteria   HLH-2004   Cellular Cytotoxicity Assays   Genetic Diagnosis  

Revisited Diagnostic Guidelines for Familial Hemophagocytic Lymphohistiocytosis (FHL) Based on HLH-2004: Updates to Diagnostic Criteria and Development of Multipathway Diagnostic Strategies Introduction Familial hemophagocytic lymphohistiocytosis (FHL) is a severe hyperinflammatory disease characterized by abnormal accumulation of macrophages and l...